Alpha Tau Medical
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Alpha Tau Medical sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Alpha Tau Medical: 5 sponsored US clinical trials, 4 recruiting.
Alpha Tau Medical sponsors 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. The most-studied condition in this pipeline is Recurrent Squamous Cell Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Alpha Tau Medical sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
NCT06615635
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
NCT06910306
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT06698458
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253
Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors
NCT04377360
What is open in the Alpha Tau Medical pipeline
4 recruiting of 5 indexed (80% open); 1 completed (20%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Recurrent Squamous Cell Carcinoma (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alpha Tau Medical: open-pipeline peers nationwide
Peers matched on 5 registered trials and 80% open enrollment, not the therapeutic-area sidebar.
Alpha Tau Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 80% open enrollment (± trial volume)
- Buck Institute for Research on Aging · 80% recruiting · 5 trials
- IDEAYA Biosciences · 80% recruiting · 10 trials
- MapLight Therapeutics · 80% recruiting · 5 trials
- Mirador Therapeutics · 80% recruiting · 5 trials
Related
What to do with this Alpha Tau Medical page
5 registered trials is a research-attention snapshot, not an endorsement of Alpha Tau Medical or any single study.
- 4 of Alpha Tau Medical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Squamous Cell Carcinoma is the condition Alpha Tau Medical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alpha Tau Medical pipeline card: 5 registered trials from official public datasets.Report a data error.